Welcome!

News Feed Item

Data Demonstrating the Ability of ChemoFx® to Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior to Treatment Published by the American Journal of Obstetrics and Gynecology

Precision Therapeutics, a life-science company dedicated to improving patient outcomes in gynecologic cancer, today announced that a study evaluating the ability of the ChemoFx® chemoresponse assay to identify resistance to first-line treatment in ovarian cancer has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).

The study, titled, A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian Cancer, evaluated the association of ChemoFx® results with disease progression for 276 FIGO stage III-IV ovarian, fallopian and peritoneal cancer patients treated with the standard of care first-line therapy carboplatin/paclitaxel. Patients whose tumors were scored as resistant by the ChemoFx test to carboplatin, were at significantly increased risk of disease progression compared to those with non-resistant tumors (median PFS: 11.8 vs. 16.6 months, respectively, p<0.001). The association was confirmed after adjusting for other clinical factors (HR=1.71, 95% CI=1.12-2.62, p=0.013). In addition to identifying platinum-resistant patients, the study also demonstrated the ability of ChemoFx to identify agents to which a patient’s tumor is sensitive. For 59% of those patients whose tumors proved resistant to carboplatin, at least one other commonly utilized agent was determined by ChemoFx to be sensitive or intermediately sensitive, indicating that these patients may benefit from alternative clinically validated treatments. These results further demonstrate the capability of the ChemoFx test to inform treatment decisions beyond the carboplatin/paclitaxel standard of care, particularly in cases where patients are unlikely to respond to the routine treatment.

Dr. Thomas C. Krivak, M.D., assistant director of gynecologic oncology and director of clinical research in gynecologic oncology at Allegheny Health Network, Department of Obstetrics and Gynecology, in Pittsburgh PA, is the primary author of the study.

“What the findings of this study essentially mean for ovarian cancer patients is that resistance to standard platinum chemotherapy treatment can now be determined much earlier in the treatment pathway with the use of ChemoFx results,” said Dr. Krivak. “Earlier determination of platinum resistance may help physicians choose the more effective treatments upfront, minimizing exposure to ineffective and often expensive therapy. Additionally, having further information about the tumor and chemotherapy resistance could substantiate augmenting standard of care with a third chemotherapy or with targeted agents.”

In addition to these findings, a recent, prospective study on recurrent ovarian cancer patients showed a 14 month improvement in median overall survival when patients were administered treatments identified as sensitive by ChemoFx vs. the non-sensitive treatments. “The combination of information this test provides is invaluable to physicians who are compelled to choose from a range of equivalent treatment recommendations without prior knowledge of how an individual patient may respond to any given treatment,” said Sean McDonald, CEO of Precision. “The ability of this test to determine platinum resistance in primary ovarian cancer patients and to demonstrate longer overall survival by 14 months in recurrent ovarian cancer, makes it an instrumental tool in helping to improve outcomes in ovarian cancer patients.”

About ChemoFx®

ChemoFx® is a proprietary drug response marker, which categorizes an individual patient’s tumor response to a range of standard chemotherapeutic options. Recently published prospective data demonstrates a 14-month improvement in overall survival (OS) when recurrent ovarian cancer patients are treated with therapy indicated as ‘responsive’ by the assay. ChemoFx may also help identify platinum-resistant/refractory primary ovarian patients earlier in their treatment pathway, aiding physicians with the selection of effective treatment upfront for patients newly diagnosed. Precision Therapeutics currently receives ChemoFx® specimens from over 270 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalizing cancer care and improving patient outcomes. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s other leading products for personalized cancer care include:

  • BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis.
  • GeneFx® Colon, an expression–based gene signature developed for FFPE tissue from stage II colon cancer patients. Following surgery, GeneFx Colon assesses a patient’s risk of recurrence within 5 years.

For more information, visit www.precisiontherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DX World EXPO, LLC, a Lighthouse Point, Florida-based startup trade show producer and the creator of "DXWorldEXPO® - Digital Transformation Conference & Expo" has announced its executive management team. The team is headed by Levent Selamoglu, who has been named CEO. "Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation," he said in making the announcement.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to gre...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...